Having trouble accessing articles? Reset your cache.

Masitinib: Phase II data

A double-blind Phase II trial in 35 patients showed that masitinib met the primary endpoint of significantly improving ADAS-Cog scores from baseline

Read the full 220 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE